RxDoctor Payments Data

Samuel Markind

Neurology · Danbury, CTNPI 1427053404

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,750 of the $2,210 with a category attached, or 79.2%. Eli Lilly accounts for 79.2% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $1,750 and has fallen 94.9% since, to $89 in 2022.

$2,210in general payments, 2019–2025

Across 23 payments — averaging $96.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$2K
  • Lilly USA, LLC$89
  • Novartis$62
  • Biogen$52
  • Sunovion Pharmaceuticals Inc.$41
  • CSL Behring$29
  • plus $188 from 10 others
$232,550in research payments, 2019–2025

Across 30 payments — averaging $7751.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$174K
  • Genentech, Inc.$58K

What the payments were for

  • Consulting fees$1,75079%
  • Food & beverage$46021%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,210 in reported general payments places this provider in the 60th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Other neurology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →